Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 17/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.50 |
| ▸ | FEN1 | P39748 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29118749 | 0.87 | SCN9A (0.43) | SCN9ACYP2C9ALOX5APFEN1CYP3A4 | |
| SCHEMBL7803911 | 0.86 | ADRA2A (0.43) | SCN9ACYP2C9ALOX5APFEN1CYP3A4 | |
| SCHEMBL14003435 | 0.83 | MAOB (0.44) | SCN9AKDM4EMAPT | |
| SCHEMBL5545746 | 0.81 | SCN9A (0.60) | SCN9ACYP2C9CYP3A4CYP2D6TRPA1 | |
| SCHEMBL14744155 | 0.81 | NCOA1 (0.51) | SCN9ACYP2C9ALOX5APFEN1CYP3A4 | |
| SCHEMBL1271677 | 0.80 | NCOA1 (0.55) | CYP3A4KDM4EMAPT | |
| SCHEMBL5545741 | 0.80 | SCN9A (0.56) | SCN9ACYP2C9CYP3A4CYP2D6TRPA1 | |
| SCHEMBL29788132 | 0.80 | FFAR4 (0.55) | SCN9ACYP2C9ALOX5APFEN1CYP3A4 | |
| SCHEMBL306822 | 0.80 | FFAR4 (0.55) | SCN9ACYP2C9ALOX5APFEN1CYP3A4 | |
| SCHEMBL1400390 | 0.80 | ALOX5AP (0.55) | SCN9AALOX5APFEN1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087072-A2 | SPIROINDOLINE ANTIPARASITIC DERIVATIVES | Zoetis Services LLC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160296499-A1 | Spiroindoline Antiparasitic Derivatives | ZOETIS SERVICES LLC | 2016-10-13 | — | — | US | disclosed |
| CN-105829311-A | SPIROINDOLINE ANTIPARASITIC DERIVATIVES | 硕腾服务有限责任公司 | 2016-08-03 | — | — | CN | disclosed |
| WO-2015100232-A2 | SPIROINDOLINE ANTIPARASITIC DERIVATIVES | ZOETIS SERVICES LLC (US) | 2015-07-02 | — | — | WO | disclosed |
| US-8642788-B2 | Activators of executioner procaspases 3, 6 and 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| EP-1694654-B1 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME (US) | 2011-03-02 | — | — | EP | disclosed |
| EP-1694654-B1 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2237784-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | The Regents of the University of California (US) | 2010-10-13 | — | — | EP | disclosed |
| EP-2200436-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326726-B2 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1694654-A2 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060183897-A1 | Biaryl substituted triazoles as sodium channel blockers | MERCK & CO., INC. | 2006-08-17 | — | — | US | disclosed |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2006-01-26 | — | — | US | disclosed |
| EP-1606269-A1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050119261-A1 | Biaryl substituted triazoles as sodium channnel blockers | MERCK SHARP & DOHME LLC | 2005-06-02 | — | — | US | disclosed |
| WO-2005047270-A2 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2004083190-A1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO. INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083189-A1 | BIARYL SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296499-A1 | Spiroindoline Antiparasitic Derivatives | PKD2, PKD1, AVPR2 | SCN9A 371/4885CYP2C9 277/4885ALOX5AP 1773/4885 |
| US-20050119261-A1 | Biaryl substituted triazoles as sodium channnel blockers | SCN3A, TRPV1, KCNN3 | SCN9A 67/4885CYP2C9 279/4885ALOX5AP 2444/4885 |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | CASP7, CASP3, CASP6 | SCN9A 4326/4885CYP2C9 4309/4885ALOX5AP 1578/4885 |
| US-20060183897-A1 | Biaryl substituted triazoles as sodium channel blockers | SCN3A, TRPV1, SCN1B | SCN9A 56/4885CYP2C9 349/4885ALOX5AP 2474/4885 |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | TRPV1, SCN3A, SCN5A | SCN9A 50/4885CYP2C9 574/4885ALOX5AP 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.